Protagonist Therapeutics, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Protagonist Therapeutics is a clinical-stage biopharmaceutical company developing peptide-based therapies for hematology, blood disorders, and inflammatory and immunomodulatory diseases. Its principal programs are rusfertide, partnered with Takeda, and JNJ-2113, partnered with Johnson & Johnson. The company operates as one business segment.
This Form 10-Q covers the three months ended March 31, 2024. The financial statements are unaudited and prepared under U.S. GAAP. The company had 58.6 million common shares outstanding as of March 31, 2024.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| License and collaboration revenue | $255.0 million | $0 |
| Research and development expense | $33.7 million | $27.4 million |
| General and administrative expense | $14.9 million | $8.6 million |
| Total operating expenses | $48.6 million | $36.0 million |
| Income (loss) from operations | $206.3 million | $(36.0) million |
| Net income (loss) | $207.3 million | $(33.7) million |
| Diluted earnings (loss) per share | $3.26 | $(0.67) |
| Cash used in operating activities | $27.4 million | $34.3 million |
Q1 2024 operating and net margins were approximately 81% of reported revenue, but these margins were primarily driven by the one-time recognition of the Takeda upfront payment and are not representative of product-sales economics. Interest income was $4.4 million, compared with $2.5 million in the prior-year period. Income tax expense was $3.3 million, compared with none in Q1 2023.
At March 31, 2024, cash and cash equivalents were $172.6 million, marketable securities were $150.1 million, and total cash, cash equivalents and marketable securities were $322.6 million, compared with $341.6 million at December 31, 2023. Total assets were $629.3 million and stockholders’ equity was $560.4 million. The balance sheet reports no debt; total liabilities were $68.8 million, including $45.0 million of deferred revenue.
The accumulated deficit declined to $408.4 million from $615.7 million at year-end 2023 because of the Q1 net income. The company stated that its existing cash, cash equivalents and marketable securities are expected to fund operations for at least the next twelve months based on current plans.
Material changes versus the prior comparable period
- Revenue increased by $255.0 million, reflecting the Takeda collaboration; no collaboration revenue was recognized in Q1 2023.
- Of the $300.0 million Takeda transaction price, $254.1 million was recognized upon delivery of the rusfertide license and $0.9 million was recognized for development services. The remaining $45.0 million was recorded as deferred revenue.
- Research and development expense increased 23% to $33.7 million, driven primarily by higher rusfertide Phase 3 VERIFY and contract manufacturing costs and increased preclinical and discovery spending.
- General and administrative expense increased 73% to $14.9 million, primarily because of $4.6 million of additional advisory and legal fees related to the Takeda transaction, higher stock-based compensation, and increased personnel costs.
- Operating cash use improved by $6.9 million year over year, although the company still used $27.4 million of operating cash.
- Financing cash inflow declined to $7.2 million from $26.5 million because there were no Q1 2024 ATM sales; Q1 2023 included $24.3 million of ATM proceeds.
- Shares outstanding increased during the quarter through equity incentive and employee stock purchase plans and the net exercise of pre-funded warrants. Approximately 2.62 million pre-funded warrants remained outstanding at March 31, 2024.
Guidance, outlook, commentary, risks and unusual items
- Enrollment in the approximately 250-patient Phase 3 VERIFY trial of rusfertide has been completed. Management expects top-line results for the 32-week primary efficacy endpoint by the end of Q1 2025 and potentially an FDA NDA filing in Q4 2025.
- The company expects results from an ongoing two-year rat carcinogenicity study for rusfertide by the end of 2024.
- Under the Takeda agreement, the company may receive up to $330.0 million in additional worldwide development, regulatory and commercial milestones, plus 10% to 17% tiered royalties on ex-U.S. net sales. The company and Takeda will generally share U.S. profits and losses equally, subject to opt-out rights that could provide enhanced milestone and royalty economics.
- The company received the $300.0 million Takeda upfront payment in April 2024, after the quarter-end. The payment was recorded as a receivable at March 31, 2024.
- Potential near-term Takeda milestones include $25.0 million upon successful achievement of the VERIFY primary endpoint and $50.0 million upon FDA approval of a rusfertide NDA, or $75.0 million if the company exercises its full U.S. opt-out right.
- JNJ-2113 is being advanced by J&J in multiple Phase 3 psoriasis trials and a Phase 2b ulcerative colitis trial. Protagonist has earned $172.5 million of nonrefundable JNJ payments through the filing date and remains eligible for additional milestones and 6% to 10% royalties.
- The company expects research and development expenses to increase in the near term as it advances rusfertide, preclinical programs, and discovery activities. Management cannot reliably estimate the timing or total cost of development or future product revenue.
- Key risks include failure or delay of clinical trials, adverse safety findings, regulatory nonapproval, manufacturing and supply-chain interruptions, dependence on Takeda and J&J, collaboration termination, intellectual-property challenges, competition, macroeconomic disruption, inflation, and the potential need for additional capital.
- The company has no approved products, no product-sales revenue, and no historical commercial revenue. The Q1 profit was substantially dependent on the Takeda upfront payment.
- On May 6, 2024, the company amended its Newark facility lease for 60,575 rentable square feet. The lease begins July 1, 2024, or later upon completion of tenant improvements, and runs through November 2029, with initial monthly base rent of $3.53 per square foot and 3.5% annual increases.
- Management reported effective disclosure controls and procedures and no material changes in internal control over financial reporting. The company reported no material legal proceedings.
Important facts for investors to verify
- Whether the $300.0 million Takeda upfront payment was received in April 2024 as disclosed and how the resulting cash balance affects the company’s operating runway.
- Progress, safety findings, and top-line timing for the VERIFY Phase 3 trial, including the expected Q1 2025 data and potential Q4 2025 NDA filing.
- The treatment and timing of the $45.0 million deferred revenue balance and any future milestone or royalty recognition under the Takeda agreement.
- The company’s intended exercise or non-exercise of the Takeda U.S. profit-and-loss sharing opt-out rights.
- Development progress, milestone eligibility, and collaboration status for JNJ-2113, including J&J’s control over development activities.
- Cash burn excluding collaboration-related accounting effects, expected research and development spending, and whether additional financing will be required.
- Outstanding pre-funded warrants and other equity awards, including their potential dilutive impact.
- Rusfertide’s long-term safety and carcinogenicity data, regulatory requirements, manufacturing readiness, and competitive position in polycythemia vera.